Ischemia modified albumin and carbonyl protein as potential biomarkers of protein oxidation in hemodialysis

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 450-454

  Albarello, Kassiano ^a   dos Santos, Gélson Antônio ^b   Bochi, Guilherme Vargas ^c   Sangoi, Manuela Borges ^c   Almeida, Taís Corrêa ^c   Paz da Silva, José Edson ^c   Garcia, Solange Cristina ^d   Moresco, Rafael Noal ^c  

^a UNIVERSITY OF PASSO FUNDO   (Brazil)

^b Clínica Renal do Extremo Oeste   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Chronic kidney disease; Hemodialysis; Ischemia modified albumin; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; CARBONYL DERIVATIVE; HEMOGLOBIN; ISCHEMIA MODIFIED ALBUMIN; SERUM ALBUMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORRELATIONAL STUDY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN OXIDATION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84858443111     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.031     Document Type: Article

References (55)

1. Meguid El Nahas A., Bello A.K. Chronic kidney disease: the global challenge. Lancet 2005, 365:331-340.
2. Canaud B., Cristol J.P., Morena M., Leray-Moragues H., Bosc J.Y., Vaussenat F. Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purif 1999, 17:99-106.
3. Ward R., McLeish K.R. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 1995, 5:1697-1702.
4. Descamps-Latscha B., Drueke T., Witko-Sarsat V. Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001, 14:193-199.
5. Witko-Sarsat V., Gausson V., Nguyen A.T., Touam M., Drüeke T., Santangelo F., et al. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003, 64:82-91.
6. Galli F. Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant 2007, 5:20-36.
7. Cichota L.C., Moresco R.N., Duarte M.M.M.F., Paz da Silva J.E. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal 2008, 22:1-5.
8. Roy D., Quiles J., Gaze D.C., Collinson P., Kaski J.C., Baxter G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 2006, 92:113-114.
9. Bhagavan N.V., Lai E.M., Rios P.A., Yang J., Ortega-Lopez A.M., Shinoda H., et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003, 49:581-585.
10. Sharma R., Gaze D.C., Pellerin D., Mehta R.L., Gregson H., Streather C.P., et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006, 47:493-502.
11. Sharma R., Gaze D.C., Pellerin D., Mehta R.L., Gregson H., Streather C.P., et al. Evaluation of ischaemia-modified albumin as a marker of myocardial ischaemia in end-stage renal disease. Clin Sci 2007, 113:25-32.
12. Turedi S., Cinar O., Yavuz I., Mentese A., Gunduz A., Karahan S.C., et al. Differences in ischemia-modified albumin levels between end stage renal disease patients and the normal population. J Nephrol 2010, 23:335-340.
13. Stadtman E.R., Moskovitz J., Levine R.L. Oxidation of methionine residues of proteins: biological consequences. Antioxid Redox Signal 2003, 5:577-582.
14. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
15. Kaefer M., Piva S.J., De Carvalho J.A., Da Silva D.B., Becker A.M., Coelho A.C., et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010, 43:450-454.
16. Lippi G., Montagnana M., Salvagno G.L., Guidi G.C. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007, 45:261-262.
17. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990, 186:464-478.
18. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
19. Halliwell B., Gutteridge J., Cross C. Free radicals, antioxidants, and human disease: where are we now?. J Lab Clin Med 1992, 119:598-620.
20. Loughrey C.M., Young I.S., Lightbody J.H., McMaster D., McNamee P.T., Trimble E.R. Oxidative stress in haemodialysis. QJM 1994, 87:679-683.
21. Gastaldello K., Husson C., Wens R., Vanherweghem J.L., Tielemans C. Role of complement and platelet-activating factor in the stimulation of phagocytosis and reactive oxygen species production during hemodialysis. Nephrol Dial Transplant 2000, 15:1638-1646.
22. Descamps-Latscha B., Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis. Nephrologie 2003, 24:377-379.
23. Montagnana M., Lippi G., Tessitore N., Salvagno G.L., Targher G., Gelati M., et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal 2008, 22:59-65.
24. Kiyici A., Mehmetoǧlu I., Karaoǧlan H., Atalay H., Solak Y., Türk S. Ischemia-modified albumin levels in patients with end-stage renal disease patients on hemodialysis: does albumin analysis method affect albumin-adjusted ischemia-modified albumin levels?. J Clin Lab Anal 2010, 24:273-277.
25. Ward R.A., McLeish K.R. Oxidant stress in hemodialysis patients: what are the determining factors?. Artif Organs 2003, 27:230-236.
26. Dursun E., Dursun B., Suleymanlar G., Ozben T. Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus. Acta Diabetol 2005, 42:123-128.
27. Himmelfarb J., McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001, 60:358-363.
28. Duarte M.M.M.F., Rocha J.B.T., Moresco R.N., Duarte T., Da Cruz I.B., Loro V.L., et al. Association between ischemia modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009, 42:666-671.
29. Bar-Or D., Curtis C.G., Sullivan A., Rael L.T., Thomas G.W., Craun M., et al. Plasma albumin cysteinylation is regulated by cystathionine beta-synthase. Biochem Biophys Res Commun 2004, 325:1449-1453.
30. Bar-Or D., Rael L.T., Bar-Or R., Slone D.S., Mains C.W., Rao N.K., et al. The cobalt-albumin binding assay: insights into its mode of action. Clin Chim Acta 2008, 387:120-127.
31. Morena M., Cristol J.P., Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 2000, 18:191-199.
32. Kotani K., Kimura S., Kinugasa E., Ogata H., Caccavello R., Taniguchi N., et al. Correlation between ischaemia-modified albumin and intermediate-density lipoprotein in haemodialysis patients with end-stage renal disease. J Int Med Res 2011, 39:1541-1545.
33. Kotani K., Kimura S., Gugliucci A. Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease. J Physiol Biochem 2011, 67:437-441.
34. Van Campenhout A., Van Campenhout C., Lagrou A., Manuel-y-Keenoy B. Iron-induced oxidative stress in hemodialysis patients: a pilot study on the impact of diabetes. Biometals 2008, 21:159-170.
35. Kuo K.L., Hung S.C., Weim Y.H., Tarng D.C. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008, 19:1817-1826.
36. Garcia-Fernandez N., Echeverria A., Sanchez-Ibarrola A., Páramo J.A., Coma-Canella L. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology (Carlton) 2010, 15:178-183.
37. Sela S., Shurtz-Swieski R., Shapiro G., Nasser L., Hamzi M., Shasha S.M., et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int Suppl 2001, 78:159-163.
38. Lim P.S., Wei Y.H., You Y.L., Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999, 14:2680-2687.
39. Herrera J., Nava M., Romero F., Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001, 37:750-757.
40. Roob J.M., Khoschsorur G., Tiran A., Horina J.H., Holzer H., Winklhofer-Roob B.M. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000, 11:539-549.
41. Borderie D., Allanore Y., Meune C., Devaux J.Y., Ekindjian O.G., Kahan A. High ischemia modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004, 50:2190-2193.
42. Himmelfarb J., Hakim R.M. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003, 12:593-598.
43. Luciak M., Tiznadel K. Free oxygen species metabolism during hemodialysis with different membranes. Nephrol Dial Transplant 1991, 6:66-70.
44. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal failure: an emerging threat to patient outcome. Nephrol Dial Transplant 2003, 18:1272-1280.
45. Terawaki H., Takada Y., Era S., Funakoshi Y., Nakayama K., Nakayama M., et al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial 2010, 14:465-471.
46. Ward R.A., Ouseph R., McLeish K.R. Effects of high-flux hemodialysis on oxidant stress. Kidney Int 2003, 63:353-359.
47. Pavone B., Sirolli V., Giardinelli A., Bucci S., Forli F., di Cesare M., et al. Plasma proteincarbonylation in chronic uremia. J Nephrol 2011, 24:453-464.
48. Dursun E., Dursun B., Süleymanlar G., Ozben T. Carbonyl stress in chronic renal failure: the effect of haemodialysis. Ann Clin Biochem 2005, 42:64-66.
49. Varan H.I., Dursun B., Dursun E., Ozben T., Suleymanlar G. Acute effects of hemodialysis on oxidative stress parameters in chronic uremic patients: comparison of two dialysis membranes. Int J Nephrol Renovasc Dis 2010, 3:39-45.
50. Danielski M., Ikizler T.A., McMonagle E., Kane J.C., Pupim L., Morrow J. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003, 42:286-294.
51. Carrard G., Bulteau A.L., Petropoulos I., Friguet B. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 2002, 34:1461-1474.
52. Stadtman E.R., Levine R.L. Protein oxidation. Ann N Y Acad Sci 2000, 899:191-208.
53. Tetta C., Biasioli S., Schiavon R., Inguaggiato P., David S., Panichi V., et al. An overview of haemodialysis and oxidant stress. Blood Purif 1999, 17:118-126.
54. Himmelfarb J., Ault K.A., Holbrook D., Leeber D.A., Hakim R.M. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 1995, 4:178-186.
55. Ward R.A., McLeish K.R. Hemodialysis with cellulose membranes primes the neutrophil oxidative burst. Artif Organs 1995, 19:801-807.